Fortunately, some of the clinical trials of PI3K/AKT inhibitors have demonstrated encouraging clinical activity in relapsed and relapsed/refractory (R/R) MM [336–339] (NCT01002248; NCT01476137; NCT00881946) (Tables 2 and 3). Here, PIK3CD is linked to Miyoshi myopathy.